StockData
GT Biopharma, Inc. logo

GT Biopharma, Inc. (GTBP) stock

GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30
$3.43+0.25 (+7.86%)

Close on Nov 18, 2026Market cap $154.73MP/E –Yield –

GT Biopharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

GT Biopharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$14.43M. For fiscal 2025 it was -$12.91M. The highest annual figure on record is -$442.00K in fiscal 2013.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.91M–
FY2024Dec 31, 2024-$12.90M–
FY2023Dec 31, 2023-$8.85M–
FY2022Dec 31, 2022-$15.22M–
FY2021Dec 31, 2021-$15.61M–
FY2020Dec 31, 2020-$7.26M–
FY2019Dec 31, 2019-$3.66M–
FY2018Dec 31, 2018-$10.68M–
FY2017Dec 31, 2017-$5.43M–
FY2016Dec 31, 2016-$1.93M–
FY2015Dec 31, 2015-$4.66M–
FY2014Dec 31, 2014-$1.75M–
FY2013Dec 31, 2013-$442.00K–
FY2012Dec 31, 2012-$987.00K–
FY2011Dec 31, 2011-$963.00K–
FY2010Dec 31, 2010-$1.54M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.26M–
Q1 FY2026Mar 31, 2026-$2.47M–
Q4 FY2025Dec 31, 2025-$4.02M–
Q3 FY2025Sep 30, 2025-$3.68M–
Q2 FY2025Jun 30, 2025-$3.01M–
Q1 FY2025Mar 31, 2025-$2.20M–
Q4 FY2024Dec 31, 2024-$2.47M–
Q3 FY2024Sep 30, 2024-$2.74M–
Q2 FY2024Jun 30, 2024-$3.54M–
Q1 FY2024Mar 31, 2024-$4.16M–
Q4 FY2023Dec 31, 2023-$2.05M–
Q3 FY2023Sep 30, 2023-$1.96M–
Q2 FY2023Jun 30, 2023-$1.94M–
Q1 FY2023Mar 31, 2023-$2.91M–
Q4 FY2022Dec 31, 2022-$4.30M–
Q3 FY2022Sep 30, 2022-$2.92M–
Q2 FY2022Jun 30, 2022-$2.79M–
Q1 FY2022Mar 31, 2022-$5.22M–
Q4 FY2021Dec 31, 2021-$3.71M–
Q3 FY2021Sep 30, 2021-$3.93M–
Q2 FY2021Jun 30, 2021-$4.29M–
Q1 FY2021Mar 31, 2021-$3.68M–
Q4 FY2020Dec 31, 2020-$1.93M–
Q3 FY2020Sep 30, 2020-$1.70M–
Q2 FY2020Jun 30, 2020-$3.41M–
Q1 FY2020Mar 31, 2020-$223.00K–
Q4 FY2019Dec 31, 2019-$485.00K–
Q3 FY2019Sep 30, 2019-$1.13M–
Q2 FY2019Jun 30, 2019-$1.09M–
Q1 FY2019Mar 31, 2019-$961.00K–
Q4 FY2018Dec 31, 2018-$1.24M–
Q3 FY2018Sep 30, 2018-$3.43M–
Q2 FY2018Jun 30, 2018-$1.77M–
Q1 FY2018Mar 31, 2018-$4.23M–
Q4 FY2017Dec 31, 2017-$2.15M–
Q3 FY2017Sep 30, 2017-$2.24M–
Q2 FY2017Jun 30, 2017-$391.00K–
Q1 FY2017Mar 31, 2017-$650.00K–
Q4 FY2016Dec 31, 2016-$135.00K–
Q3 FY2016Sep 30, 2016-$563.00K–

More GT Biopharma figures

See a number that looks wrong?